mitoxantrone has been researched along with Recrudescence in 232 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (3.45) | 18.7374 |
| 1990's | 84 (36.21) | 18.2507 |
| 2000's | 79 (34.05) | 29.6817 |
| 2010's | 52 (22.41) | 24.3611 |
| 2020's | 9 (3.88) | 2.80 |
| Authors | Studies |
|---|---|
| Edan, G; Kerbrat, A; Le Corre, G; Le Page, E; Le Port, D; Lefort, M; Leray, E; Michel, L; Rizzato, C | 1 |
| Ba, D; Li, H; Liu, R; Tang, Y; Zhang, P | 1 |
| Bérard, N; Cabre, P; Chaumont, H; Karam, JP; Lannuzel, A; Lobjois, Q; Signate, A; Tressieres, B | 1 |
| Amrein, PC; Attar, E; Ballen, KK; Behnan, T; Bergeron, MK; Bertoli, C; Blonquist, TM; Brunner, AM; Burke, M; Chen, YB; Connolly, C; Duong, VH; Emadi, A; Fathi, AT; Foster, JE; Graubert, TA; Hasserjian, RP; Hobbs, G; Hock, H; Lescinskas, C; Lesho, P; Macrae, M; Mann, ML; McAfee, SL; McGregor, K; Moran, JA; Narayan, R; Neuberg, DS; Preffer, FI; Rae, J; Ramos, AY; Som, TT; Story, JL; Vartanian, MK; Wey, MC | 1 |
| Al-Kali, A; Betcher, JA; Foran, J; Meyer, M; Palmer, J; Scheckel, CJ | 1 |
| Abbenante, MC; Arpinati, M; Baccarani, M; Baldazzi, C; Bertamini, L; Bochicchio, MT; Bonifazi, F; Caso, L; Cavo, M; Cristiano, G; Curti, A; de Polo, S; Fontana, MC; Marconi, G; Martinelli, G; Nanni, J; Olivi, M; Ottaviani, E; Paolini, S; Papayannidis, C; Parisi, S; Ragaini, S; Sartor, C; Sessa, M; Talami, A; Testoni, N | 1 |
| Agrawal, V; Arain, S; Cahill, K; Calip, GS; Christian, S; Esen, A; Griffin, S; Khan, I; Konig, H; Odenike, O; Patel, P; Quigley, JG; Shergill, A; Stock, W; Sweiss, K | 1 |
| Foo, EC; Ford, HL; Lily, O; Russell, M | 1 |
| Aotsuka, N; Doki, N; Fujisawa, S; Fujiwara, SI; Gotoh, M; Ishizaki, T; Kanamori, H; Kanda, J; Kanda, Y; Kimura, SI; Miyazaki, T; Mori, T; Najima, Y; Okamoto, S; Onizuka, M; Saito, T; Sakaida, E; Shono, K; Tachibana, T; Takahashi, S; Tanaka, M; Watanabe, R | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Aktas, O; Angstwurm, K; Berthele, A; Borisow, N; Faiss, J; Fischer, K; Friede, T; Gahlen, A; Geis, C; Hartung, HP; Havla, J; Hellwig, K; Hemmer, B; Hofstadt-van Oy, U; Jarius, S; Kleinschnitz, C; Kleiter, I; Krumbholz, M; Kümpfel, T; Lauda, F; Linker, RA; Marziniak, M; Mayer, C; Neuhaus, O; Pache, F; Paul, F; Ringelstein, M; Ruprecht, K; Schuster, S; Schwab, M; Stangel, M; Stellmann, JP; Then Bergh, F; Trebst, C; Tumani, H; Wildemann, B; Young, KL; Zeltner, L; Zettl, U; Ziemann, U | 1 |
| Borschel, L; Bourquin, JP; Creutzig, U; Dworzak, M; Klingebiel, T; Klusmann, JH; Lehrnbecher, T; Rasche, M; Reinhardt, D; Zimmermann, M | 1 |
| Marrie, RA; Montalban, X | 1 |
| Darin, D; Kabdrakhmanova, G; Khamidulla, A; Urasheva, Z; Utepkaliyeva, A | 1 |
| Chartier, N; Dahan, C; Debouverie, M; Epstein, J; Guillemin, F; Mathey, G; Michaud, M; Pittion-Vouyovitch, S; Soudant, M | 1 |
| Buttmann, M | 1 |
| Deng, T; Jiang, L; Wang, D; Xiao, Y | 1 |
| Bahashwan, S; Bay, JO; Berger, MG; Douge, A; Guièze, R; Hermet, E; Lemal, R; Moluçon-Chabrot, C; Ravinet, A; Tchirkov, A; Tournilhac, O; Veronese, L; Veyrat-Masson, R | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T | 1 |
| Hamadeh, L; Hancock, J; Hoogerbrugge, P; Irving, JAE; Krishnan, S; Kuiper, RP; Moorman, AV; Parker, C; Révész, T; Saha, V; Sutton, R | 1 |
| Enriquez, CAG; Espiritu, AI; Pasco, PMD | 1 |
| Aksu, S; Aladağ, E; Büyükaşık, Y; Çiftçiler, R; Demiroğlu, H; Göker, H; Haznedaroğlu, İC; Malkan, ÜY; Okay, M; Özcebe, Oİ; Sayınalp, N | 1 |
| Ballerini, F; Cagnetta, A; Cea, M; Clavio, M; Colombo, N; Gobbi, M; Guolo, F; Lemoli, RM; Marcolin, R; Miglino, M; Minetto, P; Todiere, A | 1 |
| Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Coccia, PF; Coulter, DW; Gordon, BG; Grovas, AC; Harper, JL; Patel, SA; Sanger, WG; Warkentin, PI; Wisecarver, JL | 1 |
| Adachi, S; Hamamoto, K; Hanada, R; Hayashi, Y; Horibe, K; Imaizumi, M; Kobayashi, R; Kudo, K; Miyamura, T; Morimoto, A; Moritake, H; Nakayama, H; Shimada, A; Tabuchi, K; Taga, T; Tawa, A; Tomizawa, D; Tsuchida, M; Tsukimoto, I; Yabe, H | 1 |
| Abbi, KK; Claxton, DF; Ehmann, WC; Rybka, W | 1 |
| Ahn, JS; Chung, JS; Jo, DY; Joo, YD; Jung, SH; Kim, DY; Kim, I; Lee, JJ; Lee, KH; Moon, JH; Park, S; Shin, HJ; Sohn, SK; Song, IC; Yang, DH | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Adès, L; Beaumont, M; Bordessoule, D; Braun, T; Cereja, S; Chevret, S; Chomienne, C; Degos, L; Detourmignies, L; Dombret, H; Fenaux, P; Guerci, A; Lamy, T; Pigneux, A; Poiré, X; Raffoux, E; Recher, C; Spertini, O; Thomas, X; Tournilhac, O | 1 |
| Ahmed, T; Berenzon, D; Dralle, S; Ellis, LR; Holwerda, S; Isom, S; Klepin, HD; Lyerly, S; Manuel, M; Pardee, TS; Powell, BL | 1 |
| Amorim, S; Brice, P; Fleury, I; Harel, S; Mounier, N; Thieblemont, C | 1 |
| Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH | 1 |
| Agha, M; Amjad, A; Boyiadzis, M; Dorritie, KA; Duggal, S; Farah, R; Hou, JZ; Im, A; Lim, S; McLaughlin, B; Raptis, A; Redner, RL; Sehgal, A; Shuai, Y | 1 |
| Fu, CH; Gaynon, PS; Sun, W; Wayne, AS; Yeo, KK | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Hayashi, Y; Horibe, K; Iwamoto, S; Miyamura, T; Mizutani, S; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D | 1 |
| Bosca, I; Casanova, B; Coret, F; Pascual, AM; Sanz, MA | 1 |
| Avet-Loiseau, H; Chevallier, P; Delaunay, J; Dmytruk, N; Garand, R; Girault, S; Guillaume, T; Harousseau, JL; Hunault, M; Ifrah, N; Milpied, N; Mohty, M; Pigneux, A; Turlure, P | 1 |
| Berlanga, JJ; Besalduch, J; Brunet, S; Bueno, J; Esteve, J; Gallardo, D; Guardia, R; Heras, I; Hoyos, M; Llorente, A; Nomdedeu, J; Pérez-García, A; Ribera, JM; Sierra, J; Tormo, M | 1 |
| Bergamaschi, G; Corazza, GR; Girino, M; Gobbi, PG; Lambelet, P; Perfetti, V; Valentino, F | 1 |
| Kulcsár, G | 1 |
| Brown, AW; McGregor, BA; Osswald, MB; Savona, MR | 1 |
| Sorensen, PS | 1 |
| Jensen, PE; Koch-Henriksen, N; Oturai, AB; Petersen, T; Sellebjerg, F; Sorensen, PS | 1 |
| Komori, M; Kondo, T; Tanaka, M | 1 |
| Du, X; Huang, ZL; Li, QH; Lin, W; Lu, ZS; Weng, JY; Wu, SJ; Zhong, LY | 1 |
| Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T | 1 |
| Saida, T | 1 |
| Filanovsky, K; Shtalrid, M; Shvidel, L | 1 |
| Beer, TM; Fazli, L; Garzotto, M; Higano, CS; Janeba, N; Lange, PH; Lieberman, S; O'Brien, C; Rademacher, BL | 1 |
| Arceci, RJ; Bernstein, M; Buck, S; Chang, MN; Dahl, GV; Kshirsagar, S; Lacayo, NJ; Lum, BL; O'Brien, MM; Ravindranath, Y; Sikic, BI; Weinstein, H | 1 |
| Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H | 1 |
| Bowen, JD; Gooley, TA; Kraft, GH; Nash, RA; Wundes, A | 1 |
| Comi, G; Esposito, F; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Radaelli, M; Rocca, MA; Rodegher, M; Sormani, MP | 1 |
| Friesenhahn, V; Heymanns, J; Kleboth, K; Köppler, H; Mergenthaler, U; Thomalla, J; Weide, R | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Schrappe, M | 1 |
| Advani, AS; Ali-Osman, F; Barker, A; Beaven, A; Copelan, E; de Castro, CM; Diehl, LF; Kalaycio, M; Moore, JO; Rizzieri, DA; Rybicki, L; Sekeres, MA; Shadman, M; Sobecks, R; Talea, P | 1 |
| Arnason, B | 1 |
| Artz, A; Campbell, NP; Daugherty, C; Gajria, D; Godley, LA; Green, M; Gurbuxani, S; Huo, D; Hyjek, E; Larson, RA; Larson, SM; Odenike, O; Sipkins, D; Stock, W; Thirman, M; Van Besien, K; Weiner, H; Zhang, Y | 1 |
| Bourquin, JP; Corbacioglu, S; Creutzig, U; Dworzak, MN; Reinhardt, D; Sander, A; Schrauder, A; Stary, J; Teigler-Schlegel, A; von Neuhoff, C; Zimmermann, M | 1 |
| Altman, J; Carlson-Leuer, K; Coyle, K; Frankfurt, O; Mehta, J; Newman, D; Rademaker, AW; Tallman, MS; Trifilio, SM | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Fuss, H; Hallek, M; Hurtz, HJ; Knigge, O; Köppler, H; Losem, C; Reschke, D; Schmitz, S; Weide, R; Weiß, J | 1 |
| Gao, Z; Liu, W; Song, N; Wu, X; Zhang, WJ; Zhou, G | 1 |
| Bartolesi, AM; Fanci, R; Pecile, P; Pini, G | 1 |
| Chang, CS; Cho, SF; Liu, TC | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Cabre, P; Jeannin, S; Marignier, R; Merle, H; Olindo, S; Smadja, D | 1 |
| Gibson, AD | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Boński, JZ; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, J; Hellmann, A; Kasznicki, M; Konopka, L; Robak, T; Wołowiec, D | 1 |
| Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Emmanouilides, C; Grody, W; Lill, M; Rosen, P; Rosenfelt, F; Telatar, M; Territo, M | 1 |
| Altés, A; Bellosillo, B; Besalduch, J; Bosch, F; Cobo, F; Colomer, D; Esteve, J; Ferrer, A; Giné, E; López-Guillermo, A; Montserrat, E; Perales, M; Ribera, JM; Villamor, N | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Vianelli, N; Zinzani, PL | 1 |
| Amadori, S; Buccisano, F; Coco, FL; Consalvo, MI; Cudillo, L; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Franchi, A; Lo-Coco, F; Maurillo, L; Mazzone, C; Picardi, A; Tamburini, A; Venditti, A | 1 |
| Hohlfeld, R; Jarius, S; Voltz, R | 1 |
| Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S | 1 |
| Chen, H; Gocke, CD; Gojo, I; Greer, J; Guo, C; Karp, JE; Morris, L; Pili, R; Qian, D; Tidwell, M; Zwiebel, J | 1 |
| Böck, HP; Dreyling, M; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rohrberg, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Daenen, S; Ferrant, A; Huijgens, PC; Kramer, MH; Löwenberg, B; Schouten, HC; Sonneveld, P; Steijaert, MM; van den Berg, E; van der Holt, B; van Marwijk Kooy, R; Verdonck, LF; Verhoef, GE; Wijermans, PW | 1 |
| Ahmed, T; Hoang, A; Kancherla, R; Liu, D; Qureshi, Z; Seiter, K; Waheed, F | 1 |
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Heymanns, J; Köppler, H; Pandorf, A; Weide, R | 1 |
| Agius, M; Bashir, K; Bashir, R; Cohen, BA; Collins, TE; Fox, EJ; Herndon, R; Jeffery, DR; Khan, O; Kinkel, P; Mikol, DD; Picone, MA; Rivera, V; Rizvi, SA; Tornatore, C; Zwibel, H | 1 |
| Asnafi, V; Boiron, JM; Buzyn, A; Cayuela, JM; Dombret, H; Fiere, D; Huguet, F; Lheritier, V; Macintyre, E; Reman, O; Thomas, X; Vernant, JP; Vey, N | 1 |
| Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N | 1 |
| Robinson, H; Rymes, N | 1 |
| Avet-Loiseau, H; Chevallier, P; Dubruille, V; Garand, R; Guillaume, T; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, P; Roland, V; Vigouroux, S | 1 |
| Dahmen, U; Dirsch, O; Erbel, R; Gu, YL; Ji, Y; Karoussos, IA; Wieneke, H | 1 |
| Mattle, HP | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Stiefelhagen, P | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Bartolozzi, F; Chiusolo, P; Laurenti, L; Leone, G; Marra, R; Piccirillo, N; Sica, S; Sorá, F | 1 |
| Chaperon, J; Coustans, M; Edan, G; Le Page, E; Leray, E; Taurin, G | 1 |
| Bessho, M; Higashihara, M; Kohuri, M; Niitsu, N | 1 |
| Bakshi, R; Feichter, J; Lincoff, N; Napoli, SQ; Ramanathan, M; Sharma, J; Weinstock-Guttman, B | 1 |
| Adamczyk-Cioch, M; Dmoszynska, A; Giebel, S; Holowiecki, J; Jakubas, B; Krawczyk-Kulis, M; Lewandowski, K; Nowak, K; Palynyczko, G; Skotnicki, A | 1 |
| Böck, HP; Dreyling, M; Einsele, H; Forstpointner, R; Hänel, A; Hartmann, F; Hiddemann, W; Lehmann, T; Metzner, B; Pott, C; Repp, R; Seymour, JF; Unterhalt, M; Wandt, H | 1 |
| Avvisati, G; Breccia, M; Carmosino, I; Cimino, G; Iorio, N; Latagliata, R; Lo-Coco, F; Mandelli, F; Minni, A; Petti, MC; Testi, A | 1 |
| Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M | 1 |
| Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M | 1 |
| Chott, A; Drach, J; Jager, U; Puspok, A; Raderer, M; Streubel, B; Troch, M; Turetschek, K; Wohrer, S; Zielinski, CC | 1 |
| Inamura, K; Kakuta, K; Matano, S; Munemoto, S; Nishijima, H; Okamura, T; Satoh, S; Sugimoto, T | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Marcus, R | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
| Anchukova, LV; Domnikova, NP; Gavrilova, LV; Golubeva, ME; Isaev, VG; Kaplanov, KD; Khlevnaia, NV; Khoroshko, ND; Khuazheva, NK; Kliasova, GA; Konstantinova, TS; Korobkin, AV; Kravchenko, SK; Kulikov, SM; Lapin, VA; Loginov, AB; Maksimov, AG; Mal'tsev, VI; Medvedeva, LI; Men'shakova, SN; Miliutina, GI; Moskov, VI; Obidina, NA; Parovichnikova, EN; Pilipenko, GI; Ploskikh, MA; Porokhina, OV; Pristupa, AS; Rekhtman, GB; Ryzhko, VV; Samoĭlova, OS; Savchenko, VG; Sokolov, AN; Sokolova, IV; Tumakov, VA; Zagoskina, TP; Ziuzgin, IS | 1 |
| Chaperon, J; Coustans, M; Edan, G; Le Page, E; Leray, E; Morrissey, SP; Taurin, G | 1 |
| Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N | 1 |
| Cebula, B; Giebel, S; Grosicki, S; Hołowiecki, J; Kiełbiński, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Kłoczko, J; Piatkowska-Jakubas, B; Pluta, A; Robak, T; Skotnicki, AB; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A; Zawilska, K | 1 |
| Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; de Sevilla, AF; Domingo-Doménech, E; Escoda, L; Estany, C; Galán, P; Gardella, S; López-Guillermo, A; Montoto, S; Montserrat, E; Moreno, C; Oriol, A; Pedro, C; Ribera, JM; Vivancos, P | 1 |
| Alcázar, C; Guerrero, AL; Gutiérrez, F; Iglesias, F; Laherrán, E; Martín-Polo, J; Rodríguez-Gallego, M; Tejero, MA | 1 |
| Akbulut, H; Arican, A; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoğuz, H | 1 |
| Diener, P; Link, H; Mustafa, M; Olsson, T; Sun, JB | 1 |
| Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Noguchi, M; Saito, K; Sakuma, H; Waga, K; Yamada, K; Yamato, H | 1 |
| Cawley, JC; Davies, JM; Newland, AC; Pearce, R; Phillips, JK; Reilly, JT; Sherlaw-Johnson, C | 1 |
| Bendandi, M; Tura, S; Zinzani, PL | 1 |
| Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W | 2 |
| Björkholm, M; Gahrton, G; Grimfors, G; Gruber, A; Hast, R; Järnmark, M; Juliusson, G; Killander, A; Kimby, E; Liliemark, J | 1 |
| Beni, S; Cartoni, D; De Castro, S; Funaro, S; Gasperini, C; Millefiorini, E; Morino, S; Tallarico, D | 1 |
| Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R | 1 |
| Hattori, N; Kaya, H; Matano, S; Mochizuki, Y; Nakamura, S; Okabe, Y; Okumura, H; Otake, S; Takeshima, M; Yoshida, T | 1 |
| den Boer, ML; Huismans, DR; Klumper, E; Loonen, AH; Pieters, R; Veerman, AJ | 1 |
| Archimbaud, E; Cordonnier, C; Dreyfus, F; Fenaux, P; Jaubert, J; Leblond, V; Michallet, M; Thomas, X; Travade, P; Troussard, X | 1 |
| Barraclough, B; Boyages, J; Langlands, AO; Ung, O | 1 |
| Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML | 1 |
| Welborn, JL | 1 |
| Armstrong, SG; Benger, AM; Browman, GP; McKay, KL; Meyer, RM; Singh, G | 1 |
| Byrd, RL; Cairo, MS; Cornelius, AS; Feusner, J; Gold, SH; Krill, CE; Ruymann, FB; Wells, RJ; White, ML | 1 |
| Abgrall, JF; Flesch, M; Genne, P; Maloisel, F; Moreau, P; Pignon, B; Quiquandon, I; Saddoun, A; Solary, E; Witz, F | 1 |
| Atamer, MA; Büyükkeçeci, F; Keskin, A; Tombuloğlu, M | 1 |
| Damon, LE; Linker, CA; Ries, CA; Rugo, HS | 1 |
| Angelopoulou, MK; Lafioniatis, SN; Pangalis, GA | 1 |
| Arikan, N; Yaman, LS; Yaşar, B; Yurdakul, T; Zissis, NP | 1 |
| Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V | 1 |
| Leonard, RC; Prescott, RJ | 1 |
| Gerrits, WB; Haak, HL; Kerkhofs, H; Wijermans, PW | 1 |
| Delmer, A; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 1 |
| Barnett, MJ; Klingemann, HG; Nantel, SH; Phillips, GL; Reece, DE; Shepherd, JD; Sutherland, HJ | 1 |
| Aul, C; Balleisen, L; Bartholomäus, A; Becker, K; Bettelheim, P; Hiddemann, W; Lathan, B; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R | 2 |
| Becher, R; Fonatsch, C; Gassmann, W; Haase, D; Haferlach, T; Jürgensen, C; Löffler, H; Ludwig, WD; Noak, J; Thiel, E | 1 |
| Groenewegen, A; Löwenberg, B; Sonneveld, P; Vellenga, E; Wielenga, JJ | 1 |
| Ahmed, T; Akhtar, T; Chun, H; Feldman, E; Grima, K; Helson, L; Lake, D; Mittelman, A; Puccio, C; Seiter, K | 1 |
| Chubachi, A; Endo, K; Kuriya, S; Maruyama, Y; Meguro, K; Narigasawa, Y; Sasaki, H; Sato, S; Shiga, T; Takami, H | 1 |
| Brambs, HJ; Görich, J; Hasan, I; Krämer, S; Kunze, V; Rieber, A; Rilinger, N; Sokiranski, R | 1 |
| Errante, D; Gastaldi, R; Magnani, G; Nigra, E; Nosari, AM; Spina, M; Tirelli, U; Vaccher, E | 1 |
| Cabanillas, F; Hagemeister, FB; Keating, M; McLaughlin, P; Pate, O; Romaguera, JE; Sarris, AH; Swan, F; Younes, A | 1 |
| Huismans, DR; Klumper, E; Loonen, AH; Ossenkoppele, GJ; Pieters, R; Rottier, A; Veerman, AJ; Westra, G | 1 |
| Nishikawa, K | 1 |
| Gonzalez-Gonzalez, A; Pinilla, J; Requena, A; Velasco, JG | 1 |
| Bastianello, S; Bernini, ML; Bozzao, A; Calo', A; D'Andrea, F; Gambi, D; Gasperini, C; Millefiorini, E; Morino, S; Morra, VB; Pozzilli, C; Prencipe, M; Trojano, M | 1 |
| Ahmed, T; Akhtar, T; Ascensao, J; Beer, M; Coleman, M; Cook, P; Feldman, EJ; Goldberg, R; Helson, L; Kancherla, R; Lake, DE; Mittelman, A; Preti, RA; Seiter, K | 1 |
| Agarwal, V; Ashigbi, MY; Bello, J; Venkatraj, U; Wiernik, PH | 1 |
| Hanada, R; Hongo, T; Horikoshi, Y; Sakurai, M; Yajima, S | 1 |
| Andreeff, M; Consoli, U; Estey, E; Kantarjian, H; Keating, M; Kornblau, SM; Madden, T; Newman, RA; Sanchez-Williams, G; Snell, V; Tran, HT; Zhao, S | 1 |
| Bendandi, M; Gherlinzoni, F; Magagnoli, M; Merla, E; Tura, S; Zinzani, PL | 1 |
| Ohnishi, K; Ohno, R; Shinjyo, K; Takeshita, A; Tobita, T; Yanagi, M | 1 |
| Azuma, E; Higashigawa, M; Hirayama, M; Hori, H; Ido, M; Kawasaki, H; Sakurai, M | 1 |
| Hoskin, PJ | 1 |
| Sauter, C | 1 |
| Bitran, JD; Grad, G; Grinblatt, DL; Laport, GF; Williams, SF | 1 |
| Gray, RG; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Apel, D; Maj, S; Mariańska, B; Seferyńska, I | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Borleri, G; Buelli, M; Lerede, T; Rambaldi, A | 1 |
| Bernasconi, C; Castagnola, C; Corso, A; Dabusti, M; Lazzarino, M; Lunghi, M; Tajana, M; Zappasodi, P | 1 |
| Aul, C; Büchner, T; Eimermacher, H; Grote-Metke, A; Hiddemann, W; Kerkhoff, A; Kern, W; Kubica, U; Kuse, R; Maschmeyer, G; Wörmann, B | 1 |
| Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J | 1 |
| Avramis, VI; Carcich, S; Ortega, JA; Ozkaynak, MF | 1 |
| Benner, A; Haas, R; Martin, S; Moos, M; Schulz, R | 1 |
| Bennett, JM; Lee, S; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS; Wiernik, PH | 1 |
| Bauters, F; Detourmignies, L; Dupriez, B; Fenaux, P; Jouet, JP; Morel, P; Plantier-Colcher, I; Simon, M | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, A; Malcovati, L; Martinelli, G; Pagnucco, G; Salvaneschi, L | 1 |
| Archimbaud, E; Bordessoule, D; Cony-Makhoul, P; Cordonnier, C; de Revel, T; Delair, S; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Janvier, M; Leblond, V; Marie, JP; Nicolini, F; Rousselot, P; Simon, M; Stoppa, AM; Thomas, X; Tilly, H; Troussard, X; Vekhoff, A | 1 |
| Avigdor, A; Ben-Bassat, I; Ben-Yehuda, D; Berkowicz, M; Chetrit, A; Gillis, S; Hardan, I; Lossos, I; Raanani, P; Shpilberg, O; Sofer, O | 1 |
| Appelbaum, FR; Grever, MR; Head, DR; Hynes, HE; Karanes, C; Kopecky, KJ; Kraut, EH; Lichtin, A; Nand, S; Samlowski, WE; Vial, RH | 1 |
| Berger, E; Rumbach, L | 1 |
| Avvisati, G; Biondi, A; Carlo-Stella, C; Diverio, D; Lo Coco, F; Mandelli, F; Martino, B; Meloni, G; Petti, MC; Pogliani, EM; Rossi, G; Selleri, C; Specchia, G | 1 |
| Blume, KG; Chao, NJ; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Stockerl-Goldstein, KE | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Braess, J; Büchner, T; Haferlach, T; Hiddemann, W; Kern, W; Schoch, C; Unterhalt, M; Wörmann, B | 1 |
| Appelbaum, FR; Boldt, DH; Head, DR; Karanes, C; Luthardt, FW; Norwood, T; Pugh, RP; Rankin, C; Rosen, PJ | 1 |
| Arceci, RJ; Brophy, N; Chang, M; Dahl, GV; Dunussi-Joannopoulos, K; Lacayo, NJ; Sikic, BI; Weinstein, HJ | 1 |
| Ansaloni, L; Bazzocchi, R; Bini, A; Grazia, M; Stella, F; Zompatori, M | 1 |
| Berthou, C; Buzyn, A; Cahn, JY; Chomienne, C; Cordonnier, C; de Revel, T; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Gardin, C; Gratecos, N; Guerci, A; Huguet, F; Kotoucek, P; Maloisel, F; Naccache, P; Pigneux, A; Reman, O; Sadoun, A; Stamatoullas, A; Thomas, X; Travade, P; Vekhoff, A; Vilque, JP | 1 |
| Döhner, H; Döhner, K; Schlenk, RF; van der Reijden, BA | 1 |
| Dölitzsch, C; Layer, G; Schild, HH; Strunk, H; Textor, HJ; Wilhelm, K | 1 |
| Avvisati, G; Barbui, T; Bernasconi, C; Bolufer, P; Colomer, D; Díaz-Mediavilla, J; Esteve, J; Ferrara, F; Fioritoni, G; González, JD; Gonzalez, M; Liso, V; Lo Coco, F; Mandelli, F; Martín, G; Petti, MC; Rayón, C; Ribera, JM; Rodeghiero, F; Sanz, MA | 1 |
| Kraszewska, E; Krzyzanowska, JB; Lampka, E; Meder, J; Miśkiewicz, Z; Romejko-Jarosińska, J; Walewski, J | 1 |
| Crawley, CR; Foran, JM; Gupta, RK; Johnson, PW; Johnson, SA; Lister, TA; Matthews, J; Micallef, IN; Radford, JA; Rohatiner, AZ; Summers, K; Sweetenham, JW | 1 |
| Chiusolo, P; Di Febo, AL; La Barbera, EO; Laurenti, L; Leone, G; Marra, R; Menichella, G; Piccirillo, N; Sica, S; Sorà, E; Teofili, L | 1 |
| Archimbaud, E; Cambier, N; Ecstein-Fraïssé, E; Leblond, V; Pautas, C; Reman, O; Soler-Michel, P; Taksin, AL; Thomas, X; Vekhoff, A | 1 |
| Chisesi, T; Congiu, AM; Gallamini, A; Gobbi, M; Marino, G; Mattei, D; Nati, S; Pierluigi, D; Rossi, E; Rubagotti, A; Santini, G; Sertoli, MR; Spriano, M; Truini, M; Vimercati, R | 1 |
| Ancín, I; Berlanga, JJ; Ferrá, C; Gallardo, D; González, JR; Grañena, A; Marín, D; Muñoz, J; Peris, J; Sarrá, J | 1 |
| Daibata, M; Hatakeyama, N; Hiroi, M; Kamioka, M; Miyoshi, I; Nemoto, Y; Taguchi, H | 1 |
| Cuneo, A; Liso, V; Mestice, A; Pannunzio, A; Rocchi, M; Specchia, G; Storlazzi, CT; Surace, C | 1 |
| Ghalie, R; Gregory, SA; Kraemer, K; Menduni, T; Modiano, M; Rifkin, R; Rubin, A; Vose, J | 1 |
| Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K | 1 |
| Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA | 1 |
| Auvrignon, A; Bader-Meunier, B; Baruchel, A; Couillaud, G; Dalle, JH; De Lumley, L; Gandemer, V; Lamagnere, JP; Landman-Parker, J; Leblanc, T; Leverger, G; Michel, G; Nelken, B; Perel, Y; Schaison, G; Schmitt, C; Thuret, I; Vannier, JP | 1 |
| Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN | 1 |
| Braunsteiner, H; Dietze, O; Herold, M; Nachbaur, K; Thaler, J; Vogel, W | 1 |
| Bernstein, EF; Spielvogel, RL; Topolsky, DL | 1 |
| Alessandrino, EP; Bacigalupo, A; Bernasconi, C; Carella, AM; Ficarra, F; Lazzarino, M; Locatelli, F; Morra, E; Pagnucco, G; Resegotti, L | 1 |
| Oguro, M; Sakai, C; Takagi, T | 1 |
| Amadori, S; Gherlinzoni, F; Guglielmi, C; Mandelli, F; Mazza, P; Tura, S | 1 |
| Gatzemeier, U; Groth, G; Häussingen, K; Heckmayr, M; Magnussen, H; Neuhauss, R; Pavel, JV | 1 |
| Bertino, J; Crown, JP; Gulati, S; Heelan, R; Kolitz, J; Lee, BJ; O'Brien, J; Portlock, C; Straus, DJ | 1 |
| Chan, TK; Chiu, E; Liang, R; Todd, D | 1 |
| Cuttner, J; Holland, JF; Paciucci, PA | 1 |
| Aul, CH; Büchner, T; Heinecke, A; Hiddemann, W; Maschmeyer, G; Schleyer, E; Uhrmeister, C | 1 |
| Brière, J; Desablens, B; Ghandour, C; Harousseau, JL; Milpied, N | 1 |
| Auzanneau, G; Gisselbrecht, C; Gratecos, N; Harousseau, JL; LeBlond, V; Michallet, M; Milpied, N; Sebban, C; Troussard, X; Witz, F | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Inverardi, D; Lazzarino, M; Merante, S; Morra, E; Orlandi, E; Pagnucco, G | 1 |
| Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, T; Walters, R | 1 |
| Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ | 1 |
| Levine, S; Saltzman, A | 1 |
| Knobler, RL; Lavasa, M; Lublin, FD; Viti, C | 1 |
| Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R | 1 |
| Hattori, M; Kaneko, Y; Kumai, R; Maseki, N; Sakurai, M; Sampi, K | 1 |
| Hiraki, S; Kimura, I; Miyamoto, H; Murashima, M; Ohnoshi, T; Toyata, K; Ueno, K; Ueoka, H; Yamane, T | 1 |
13 review(s) available for mitoxantrone and Recrudescence
| Article | Year |
|---|---|
[MODERN APPROACHES TO THE TREATMENT OF MULTIPLE SCLEROSIS (REVIEW AND CLINICAL CASE)].
Topics: Adolescent; Alemtuzumab; Disease Progression; Drug Administration Schedule; Female; Humans; Immunologic Factors; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroprotective Agents; Recurrence | 2018 |
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
Topics: Cardiomyopathies; Disease Progression; Epidemiologic Studies; Humans; Immunosuppressive Agents; Infections; Intercalating Agents; Leukemia, Myeloid, Acute; Leukopenia; Mitoxantrone; Neuromyelitis Optica; Randomized Controlled Trials as Topic; Recurrence; Topoisomerase II Inhibitors; Treatment Outcome | 2019 |
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Etoposide; Fatal Outcome; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Remission Induction; Reoperation; Salvage Therapy; Vidarabine; Vincristine; Young Adult | 2009 |
[Mitoxantrone for the treatment of patients with multiple sclerosis].
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Immunosuppressive Agents; Japan; Mitoxantrone; Multiple Sclerosis; Pilot Projects; Recurrence | 2009 |
[Treatment of NMO].
Topics: Acute-Phase Reaction; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Humans; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Methylprednisolone; Mitoxantrone; Neuromyelitis Optica; Plasma Exchange; Prednisolone; Pulse Therapy, Drug; Recurrence; Rituximab | 2009 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
[Diagnosis and treatment of multiple sclerosis. Update, 2003].
Topics: Acute Disease; Adjuvants, Immunologic; Analgesics; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Controlled Clinical Trials as Topic; Cross-Over Studies; Glatiramer Acetate; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-beta; Longitudinal Studies; Methylprednisolone; Mitoxantrone; Multicenter Studies as Topic; Multiple Sclerosis; Natalizumab; Peptides; Pilot Projects; Prospective Studies; Recurrence; Time Factors | 2003 |
Identifying and treating patients with suboptimal responses.
Topics: Clinical Trials as Topic; Consensus Development Conferences as Topic; Disability Evaluation; Disease Progression; Drug Resistance; Humans; Immunologic Factors; Immunosuppressive Agents; Magnetic Resonance Imaging; Mitoxantrone; Multiple Sclerosis; Recurrence | 2004 |
[Multiple sclerosis--update].
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Adult; Diagnosis, Differential; Disease Progression; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Peptides; Recurrence | 2005 |
Use of rituximab in patients with follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Follicular; Mitoxantrone; Prednisolone; Prednisone; Randomized Controlled Trials as Topic; Recurrence; Rituximab; Vincristine | 2007 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Procarbazine; Recurrence; Remission Induction; Vinblastine | 1996 |
[New therapeutic strategies in multiple sclerosis].
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents; Brain; Clinical Trials as Topic; Disease Progression; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Methylprednisolone; Mitoxantrone; Multiple Sclerosis; Neuroprotective Agents; Peptides; Polymers; Recurrence | 1999 |
Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Drainage; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Pneumothorax; Recurrence; Treatment Outcome | 2000 |
103 trial(s) available for mitoxantrone and Recrudescence
| Article | Year |
|---|---|
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Immunoconjugates; Induction Chemotherapy; Ki-1 Antigen; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Young Adult | 2020 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine | 2019 |
Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Male; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2019 |
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Rituximab; Stem Cell Transplantation; Survival Analysis; Vinblastine; Vinorelbine | 2013 |
Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Remission Induction; Treatment Outcome | 2015 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Hydroxamic Acids; Infusions, Intravenous; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Quality of Life; Recurrence; Vidarabine; Vorinostat | 2016 |
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; France; Gemtuzumab; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Time Factors; Treatment Failure; Treatment Outcome | 2008 |
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Topics: 3' Untranslated Regions; Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CTLA-4 Antigen; Cytarabine; Disease-Free Survival; Etoposide; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Recurrence; Remission Induction; Young Adult | 2009 |
Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Survival Rate; Time Factors | 2009 |
Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Agranulocytosis; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Nausea; Recurrence; Remission Induction; Young Adult | 2009 |
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Recurrence; Risk; Taxoids; Testosterone | 2010 |
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Cyclosporins; Drug Resistance, Multiple; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Young Adult | 2010 |
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Rituximab; Tumor Burden; Vidarabine | 2010 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; Drug Resistance, Multiple; Equilibrative-Nucleoside Transporter 2; Female; Fever; Gemcitabine; Gene Expression Regulation, Leukemic; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Infusions, Intravenous; K562 Cells; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Multidrug Resistance-Associated Proteins; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; U937 Cells | 2010 |
Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2012 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Fever; Humans; Hypotension; Infections; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Treatment Outcome | 2002 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine | 2002 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Stem Cells; Time Factors | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Vidarabine | 2002 |
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Predictive Value of Tests; Probability; Recurrence; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2003 |
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Microcirculation; Middle Aged; Mitoxantrone; Recombinant Proteins; Recurrence; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2004 |
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2004 |
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Regression Analysis; Survival Analysis; Treatment Outcome | 2004 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bendamustine Hydrochloride; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Outpatients; Pilot Projects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; Survival Rate; Time Factors; World Health Organization | 2004 |
Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Genotype; Humans; Immunophenotyping; Incidence; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Receptors, Antigen, T-Cell; Recurrence; Survival Rate | 2005 |
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Transplantation, Autologous | 2006 |
Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Natriuretic Peptide, Brain; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Prognosis; Recurrence; Rituximab; Survival Analysis; Survival Rate; Treatment Outcome; Troponin T | 2006 |
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Topics: Adult; Antineoplastic Agents; Central Nervous System; Disability Evaluation; Female; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Mitoxantrone; Neuromyelitis Optica; Prospective Studies; Recurrence; Treatment Outcome | 2006 |
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mitoxantrone; Poland; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Sepsis; Time Factors; Transplantation, Homologous; Vidarabine | 2006 |
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Vidarabine | 2006 |
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2007 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
[The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence; Thioguanine; Treatment Outcome | 2007 |
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Azathioprine; Brain; Demography; Disability Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Methotrexate; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Observation; Peptides; Prevalence; Recurrence | 2008 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 2007 |
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Survival Rate; Vidarabine | 2008 |
Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
Topics: Adolescent; Adult; Aged; Disability Evaluation; Female; Humans; Immunoenzyme Techniques; Immunologic Factors; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Recurrence; Retrospective Studies; Statistics, Nonparametric; Uric Acid | 2008 |
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence | 1995 |
A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance; Female; Heart Failure; Humans; Immunoglobulins; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Neutropenia; Recurrence; Sepsis; Survival Analysis; Treatment Outcome; Vincristine | 1995 |
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Vidarabine | 1995 |
Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Adducts; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prednisolone; Recurrence; Survival Analysis; Thioguanine; Vincristine | 1995 |
Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis.
Topics: Adolescent; Adult; Double-Blind Method; Echocardiography; Electrocardiography; Female; Heart; Humans; Infusions, Intravenous; Male; Mitoxantrone; Multiple Sclerosis; Prospective Studies; Recurrence; Time Factors; Ventricular Function, Left | 1995 |
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
Topics: Adult; Azacitidine; Biopsy; Blast Crisis; Bone Marrow; Cell Cycle; DNA, Neoplasm; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Outcome Assessment, Health Care; Recurrence | 1993 |
[MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisolone; Recurrence | 1995 |
Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Postoperative Care; Radiotherapy Dosage; Recurrence; Retrospective Studies; Time Factors | 1995 |
Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cytarabine; DNA Adducts; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Organoplatinum Compounds; Predictive Value of Tests; Recurrence; Remission Induction | 1994 |
Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy | 1994 |
Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Pilot Projects; Recurrence | 1993 |
Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Teniposide; Vincristine | 1993 |
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence | 1993 |
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Thioguanine | 1993 |
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Platelet Count; Recombinant Proteins; Recurrence; Remission Induction | 1996 |
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Mitoxantrone; Platinum; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure | 1995 |
[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy | 1995 |
Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednimustine; Prognosis; Prospective Studies; Recurrence; Survival Rate | 1996 |
Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone; Opportunistic Infections; Recurrence; Treatment Outcome; Vidarabine | 1996 |
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Placebos; Recurrence; Remission Induction; Treatment Outcome | 1997 |
Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vinblastine | 1997 |
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Drug Resistance, Neoplasm; Etoposide; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Recurrence | 1997 |
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vidarabine | 1997 |
Weekly chemotherapy using PMitCEBO in the palliation of recurrent non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Palliative Care; Prednisolone; Recurrence; Vincristine | 1997 |
High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Methotrexate; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Thiotepa; Time Factors; Transplantation, Autologous; Vincristine | 1998 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Patient Compliance; Recurrence; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 1998 |
[Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Topics: Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1998 |
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Over Studies; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence | 1998 |
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Critical Care; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Opportunistic Infections; Recurrence; Salvage Therapy; Time Factors | 1998 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Transplantation Conditioning | 1998 |
The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Recurrence; Repressor Proteins; Transplantation, Autologous | 1999 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Disease-Free Survival; Drug Synergism; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence | 1999 |
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Treatment Outcome | 1999 |
Therapy of molecular relapse in acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Survival Analysis; Time Factors; Tretinoin | 1999 |
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Recurrence; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1999 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Paclitaxel; Recurrence; Taxoids; Time Factors; Treatment Outcome | 1999 |
A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Treatment Outcome | 2000 |
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Etoposide; Female; Flow Cytometry; Genes, MDR; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2000 |
[Locoregional chemoperfusion with mitoxantrone for palliative therapy in bleeding bladder cancer compared with embolization].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Embolization, Therapeutic; Hemorrhage; Humans; Infusions, Intra-Arterial; Middle Aged; Mitoxantrone; Palliative Care; Perfusion; Recurrence; Survival Rate; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2000 |
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Predictive Value of Tests; Recurrence; Risk; Thioguanine; Tretinoin | 2000 |
CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vincristine | 2000 |
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; DNA, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Treatment Outcome; Vidarabine | 2000 |
MiCMA: an alternative treatment for refractory or recurrent Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Treatment Outcome | 2000 |
Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Patient Selection; Recurrence; Ventricular Function, Left | 2000 |
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Treatment Outcome; Vidarabine | 2001 |
Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Salvage Therapy; Treatment Outcome | 2000 |
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Vidarabine | 2001 |
Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Survival Rate; Time Factors; Vincristine | 2002 |
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Topics: Adult; Alopecia; Contrast Media; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Lymphocyte Count; Magnetic Resonance Imaging; Male; Methylene Blue; Methylprednisolone; Mitoxantrone; Multiple Sclerosis; Nausea; Patient Dropouts; Phlebitis; Pulmonary Embolism; Pyrrolidines; Recurrence; Severity of Illness Index; Treatment Outcome; Vomiting | 2001 |
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Mitoxantrone; Prospective Studies; Recurrence; Treatment Outcome | 2002 |
Early intensification followed by allo-BMT or auto-BMT or a second intensification in adult ALL: a randomized multicenter study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Feasibility Studies; Humans; Italy; Methotrexate; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 1992 |
Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leucovorin; Leukopenia; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Mouth Mucosa; Neoplasm Staging; Neutropenia; Recurrence; Remission Induction; Stomatitis; Stroke Volume; Survival Rate; Vincristine | 1990 |
Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone).
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms; Palliative Care; Pleural Effusion; Prospective Studies; Recurrence; Remission Induction; Survival Rate | 1991 |
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence | 1991 |
Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Lymphoma; Middle Aged; Mitoguazone; Mitoxantrone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Vinblastine | 1991 |
Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
Topics: Adult; Aged; Clinical Trials as Topic; Cytarabine; Delayed-Action Preparations; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Recurrence; Remission Induction; Time Factors | 1990 |
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence | 1990 |
116 other study(ies) available for mitoxantrone and Recrudescence
| Article | Year |
|---|---|
Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients.
Topics: Follow-Up Studies; Humans; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model.
Topics: Antigens, CD19; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line; Humans; Immunotherapy, Adoptive; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Chimeric Antigen; Recurrence; Sialic Acid Binding Ig-like Lectin 2 | 2023 |
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean.
Topics: Caribbean Region; Humans; Mitoxantrone; Neuromyelitis Optica; Prospective Studies; Recurrence | 2024 |
Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Retreatment; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2020 |
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Preoperative Care; Prognosis; Recurrence; Treatment Outcome | 2020 |
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Young Adult | 2020 |
Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Topics: Humans; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence | 2020 |
Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
Topics: Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Transplantation Conditioning; Vincristine; Young Adult | 2021 |
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
Topics: Adult; Aquaporin 4; Autoantibodies; Azathioprine; Cohort Studies; Female; Follow-Up Studies; Germany; Glatiramer Acetate; Humans; Immunotherapy; Interferon-beta; Long-Term Care; Male; Middle Aged; Mitoxantrone; Neuromyelitis Optica; Prognosis; Recurrence; Registries; Retrospective Studies; Rituximab; Treatment Outcome | 2017 |
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2018 |
Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Humans; Immunoglobulin G; Immunomodulation; Magnetic Resonance Imaging; Middle Aged; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Practice Guidelines as Topic; Precision Medicine; Pregnancy; Recurrence; Terminology as Topic; Young Adult | 2018 |
Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Topoisomerase II Inhibitors; Withholding Treatment | 2018 |
Where mitoxantrone for multiple sclerosis is still valuable in 2018.
Topics: Cohort Studies; Follow-Up Studies; Humans; Mitoxantrone; Multiple Sclerosis; Recurrence | 2018 |
Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Exosomes; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Recurrence; Young Adult | 2018 |
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2019 |
Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation\
in relapsed/refractory lymphoma
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Mitoxantrone; Recurrence; Retrospective Studies; Young Adult | 2019 |
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Recurrence; Salvage Therapy; Survival Rate | 2019 |
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine | 2013 |
Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Mitoxantrone; Recurrence; Retreatment; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Preschool; Cytarabine; Etoposide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2014 |
Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2015 |
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Belgium; Chemoradiotherapy; Female; France; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Switzerland | 2015 |
High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2015 |
Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Consolidation Chemotherapy; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Recurrence; Retrospective Studies; Rituximab; Stem Cell Transplantation; Treatment Outcome | 2016 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2016 |
Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bortezomib; Child; Child, Preschool; Dexamethasone; Female; Humans; Infant; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Vinblastine; Vinorelbine; Young Adult | 2016 |
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Core Binding Factors; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Japan; Leukemia, Myeloid, Acute; Mitoxantrone; Proto-Oncogene Proteins c-kit; Recurrence; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2017 |
Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.
Topics: Adolescent; Adult; Child; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Recurrence; Topoisomerase II Inhibitors | 2008 |
Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Male; Mitomycin; Mitoxantrone; Neoplasms; Prostatic Neoplasms; Rats; Recurrence; Vinblastine | 2009 |
How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Immunologic Factors; Interferon-beta; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroprotective Agents; Randomized Controlled Trials as Topic; Recurrence | 2009 |
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.
Topics: Adolescent; Adult; Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Denmark; Disease Progression; Enzyme-Linked Immunosorbent Assay; Humans; Middle Aged; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroprotective Agents; Recurrence; Severity of Illness Index; Treatment Outcome; Young Adult | 2009 |
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine | 2009 |
Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence | 2010 |
Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.
Topics: Adolescent; Adult; Antineoplastic Agents; Blood Cell Count; Clinical Protocols; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Patient Compliance; Patient Dropouts; Recurrence; Retrospective Studies; Safety; Stroke Volume; United States; United States Food and Drug Administration; Young Adult | 2010 |
Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.
Topics: Adolescent; Adult; Aged; Disability Evaluation; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2010 |
Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy | 2009 |
Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Idarubicin; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Recurrence; Sample Size; Treatment Outcome | 2010 |
MS Forum/MS Over the Past 17 Years.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Recurrence | 2011 |
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk; Stem Cell Transplantation; Transplantation, Homologous; Young Adult | 2012 |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents; Child; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factors; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Predictive Value of Tests; Recurrence; Translocation, Genetic; Treatment Outcome | 2011 |
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2012 |
Enhanced expression of membrane transporter and drug resistance in keloid fibroblasts.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cells, Cultured; Cytochrome P-450 CYP3A; Drug Resistance; Female; Fibroblasts; Gene Expression; Humans; Keloid; Male; Mitoxantrone; Recurrence; RNA, Messenger; Skin; Vincristine; Young Adult | 2012 |
Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Multiple, Fungal; Etoposide; Fatal Outcome; Female; Fusariosis; Fusarium; Humans; Immunocompromised Host; Itraconazole; Leukemia, Myeloid, Acute; Mitoxantrone; Neutropenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Premedication; Pyrimidines; Recurrence; Salvage Therapy; Transplantation, Homologous; Triazoles; Voriconazole | 2013 |
Isolated central nervous system relapse presenting as myeloid sarcoma of acute myeloid leukemia after allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellopontine Angle; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Magnetic Resonance Imaging; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Sarcoma, Myeloid; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2013 |
Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Cohort Studies; Disability Evaluation; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin G; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Neuromyelitis Optica; Prospective Studies; Radiography; Recurrence; Spinal Cord; Treatment Outcome | 2013 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Survival Analysis; Treatment Outcome | 2002 |
Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Orchiectomy; Prednisone; Recurrence; Remission Induction; Rituximab; Skin Neoplasms; Testis; Vincristine | 2003 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2003 |
High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Disease-Free Survival; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Prognosis; Recurrence; Remission Induction; Stem Cell Transplantation; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Extranodal mantle cell lymphoma in a prolapsed ileostomy stump.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Humans; Ileal Neoplasms; Ileostomy; Lymphoma, Mantle-Cell; Male; Mitoxantrone; Recurrence | 2005 |
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute mye
Topics: Acute Disease; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3 | 2005 |
Preliminary investigation of mitoxantrone coating on stent-grafts to inhibit neointimal proliferation.
Topics: Animals; Biopsy, Needle; Carotid Stenosis; Catheterization; Cell Proliferation; Coated Materials, Biocompatible; Disease Models, Animal; Drug Delivery Systems; Female; Immunohistochemistry; Male; Mitoxantrone; Prosthesis Failure; Rabbits; Recurrence; Reference Values; Sensitivity and Specificity; Stents; Thrombosis; Tunica Intima | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
[What was the cause of fever, neck pain and arm paresis? Normal blood picture led to error].
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arm; Cytarabine; Fever; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Neck Pain; Paresis; Prognosis; Recurrence; Remission Induction | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
[Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].
Topics: Adult; Age of Onset; Analgesics; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Time Factors | 2006 |
Late relapses in acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mastoid; Mitoxantrone; Recurrence; Time Factors; Tretinoin | 2007 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Follow-Up Studies; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Vincristine | 2006 |
Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Radiotherapy Dosage; Recurrence; Remission Induction; Vincristine | 2007 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Odds Ratio; Poland; Recurrence; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome | 2008 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematuria; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Recurrence; Survival Rate; Vincristine | 1995 |
Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity.
Topics: Animals; Antibody-Producing Cells; Autoimmunity; B-Lymphocytes; Brain; Cyclosporine; Down-Regulation; Encephalomyelitis, Autoimmune, Experimental; Guinea Pigs; Interferon-gamma; Lymph Nodes; Lymphocyte Activation; Mitoxantrone; Myelin Basic Protein; Rats; Rats, Inbred Lew; Recurrence; T-Lymphocytes | 1993 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Recurrence; Salvage Therapy; Vincristine | 1995 |
In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Bone Marrow; Child; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance; Humans; Idarubicin; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1995 |
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Treatment Outcome | 1995 |
Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Carrier Proteins; Child; Child, Preschool; Cytarabine; Drug Evaluation; Drug Resistance; Female; Gene Expression; Humans; Infant; Leukemia; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Mitoxantrone; Molecular Sequence Data; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1994 |
Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Aspartate-Ammonia Ligase; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Incidence; Methotrexate; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy | 1994 |
[Mitoxantrone-aracytine with or without quinine in the treatment of refractory or relapsed acute leukemia].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Quinine; Recurrence | 1994 |
Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Time Factors | 1994 |
Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome | 1994 |
Low grade non-Hodgkin's lymphomas: disease control with mitoxanthrone monotherapy in patients refractory to conventional therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Salvage Therapy | 1994 |
Intravesical mitoxantrone for superficial bladder tumors.
Topics: Adult; Aged; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Recurrence; Urethra; Urinary Bladder Neoplasms | 1994 |
Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chromatography, High Pressure Liquid; Cisplatin; Drug Administration Schedule; Female; Humans; Injections, Intraperitoneal; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Ovarian Neoplasms; Recurrence; Remission Induction | 1994 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pilot Projects; Prospective Studies; Recurrence; Salvage Therapy; Tumor Stem Cell Assay | 1993 |
Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction | 1993 |
Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Survival Rate; Thiotepa; Treatment Outcome; Vinblastine | 1995 |
[Superselective intra-arterial chemotherapy in therapy-refractory lymph node recurrences of breast carcinoma].
Topics: Adult; Aged; Angiography; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Infusions, Intra-Arterial; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Tomography, X-Ray Computed | 1996 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Mitoxantrone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Recurrence; Thioguanine | 1995 |
Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Family Health; Fatal Outcome; Hodgkin Disease; Humans; Lomustine; Male; Mitoxantrone; Recurrence; Remission Induction; Vinblastine | 1997 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow; Cell Survival; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Follow-Up Studies; Humans; Infant; Infant, Newborn; Life Tables; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Remission Induction; Tumor Cells, Cultured; Vincristine | 1997 |
Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cytarabine; Daunorubicin; Ear Canal; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Radiotherapy; Recurrence; Remission Induction; Salvage Therapy; Tretinoin; Vindesine | 1997 |
Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Fever; Gastrointestinal Diseases; Humans; Hydrocortisone; Hydroxyurea; Leucovorin; Male; Methotrexate; Mitoxantrone; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 1997 |
["Radiation recall"].
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Mitoxantrone; Radiodermatitis; Radiotherapy, Adjuvant; Recurrence | 1997 |
Management of acute promyelocytic leukemia relapse in the ATRA era.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Thioguanine; Treatment Outcome; Tretinoin | 1998 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cytarabine; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence; Remission Induction | 1998 |
The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; Recurrence; Remission Induction; Translocation, Genetic | 1998 |
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukemia, Myeloid; Leukopenia; Liver; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Mitoxantrone; Recurrence; Time Factors; Tissue Donors; Transplantation Chimera; Transplantation, Homologous | 1999 |
Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1999 |
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm, Residual; Prognosis; Prospective Studies; Recurrence; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Tretinoin | 2000 |
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; DNA-Binding Proteins; Etoposide; Gene Deletion; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Mitoxantrone; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Prognosis; Prospective Studies; Recurrence; Remission Induction | 2000 |
Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain; Cyclophosphamide; DNA, Viral; Doxorubicin; Etoposide; Fatal Outcome; Female; Herpesviridae Infections; Herpesvirus 6, Human; Humans; Immunity, Cellular; Immunocompromised Host; JC Virus; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Magnetic Resonance Imaging; Mitoxantrone; Nitrosourea Compounds; Papillomavirus Infections; Piperazines; Polymerase Chain Reaction; Prednisolone; Recurrence; Salvage Therapy; Vincristine; Vindesine; Virus Activation | 2001 |
Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Cytarabine; Humans; Idarubicin; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Polycystic Kidney Diseases; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2001 |
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 1992 |
Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liver; Liver Failure, Acute; Mitoxantrone; Necrosis; Recurrence; Thioguanine | 1992 |
Recurrent neutrophilic eccrine hidradenitis.
Topics: Adult; Cytarabine; Eccrine Glands; Female; Hidradenitis; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Methylprednisolone; Mitoxantrone; Recurrence; Skin | 1992 |
[Combination chemotherapy with mitoxantrone, etoposide, vindesine and prednisolone for relapsed or refractory malignant lymphoma: presence of cross-resistance to CHOP therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recurrence; Vincristine; Vindesine | 1992 |
Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction | 1991 |
Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Remission Induction | 1990 |
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Survival Rate | 1990 |
Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Recurrence; Remission Induction; Time Factors | 1989 |
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisone; Prognosis; Prospective Studies; Recurrence; Regression Analysis; Retrospective Studies; Vincristine | 1987 |
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Resistance; Hematologic Diseases; Humans; Leukemia; Mitoxantrone; Recurrence; Remission Induction; Stomatitis | 1988 |
Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Injections, Intraperitoneal; Injections, Subcutaneous; Lymph Nodes; Male; Mitoxantrone; Rats; Rats, Inbred Lew; Recurrence | 1986 |
Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone.
Topics: Acute Disease; Animals; Encephalomyelitis, Autoimmune, Experimental; Immunization; Mice; Mice, Inbred BALB C; Mitoxantrone; Recurrence | 1987 |
Phase I-II trial of mitoxantrone in acute leukemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Heart; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Liver; Male; Middle Aged; Mitoxantrone; Nausea; Recurrence; Stomatitis; Vomiting | 1985 |
[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Child; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Recurrence | 1985 |
[Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma].
Topics: Adult; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone; Prednisolone; Recurrence | 1985 |